Review



rabbit anti fancd2 antibody  (Novus Biologicals)


Bioz Verified Symbol Novus Biologicals is a verified supplier
Bioz Manufacturer Symbol Novus Biologicals manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    Novus Biologicals rabbit anti fancd2 antibody
    (A) Western blot illustrating FANCA protein loss in FANCA-deficient cell lines. (B,C) Lack of <t>FANCD2</t> monoubiquitination, a hallmark of FA pathway activation, in FANCA-deficient cells. (D,E) FANCA-deficient cells show increased vulnerability to MMC: drug response curves for CCH-SCC-FA1 ( FANCA -/- ) vs CCH-SCC-FA1 ( FANCA Compl ) (D) and DU145 WT vs DU145_ FANCA KO (E) are illustrated. (F,G) FANCA-deficient cells show increased vulnerability to cisplatin: drug response curves for CCH-SCC-FA1 ( FANCA -/- ) vs CCH-SCC-FA1 ( FANCA Compl ) (F) and DU145 WT vs DU145_ FANCA KO (G) are illustrated.
    Rabbit Anti Fancd2 Antibody, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 95/100, based on 175 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti fancd2 antibody/product/Novus Biologicals
    Average 95 stars, based on 175 article reviews
    rabbit anti fancd2 antibody - by Bioz Stars, 2026-04
    95/100 stars

    Images

    1) Product Images from "Aurora kinase A is a synthetic lethal target in FANCA-deficient cancers"

    Article Title: Aurora kinase A is a synthetic lethal target in FANCA-deficient cancers

    Journal: bioRxiv

    doi: 10.64898/2026.02.04.703705

    (A) Western blot illustrating FANCA protein loss in FANCA-deficient cell lines. (B,C) Lack of FANCD2 monoubiquitination, a hallmark of FA pathway activation, in FANCA-deficient cells. (D,E) FANCA-deficient cells show increased vulnerability to MMC: drug response curves for CCH-SCC-FA1 ( FANCA -/- ) vs CCH-SCC-FA1 ( FANCA Compl ) (D) and DU145 WT vs DU145_ FANCA KO (E) are illustrated. (F,G) FANCA-deficient cells show increased vulnerability to cisplatin: drug response curves for CCH-SCC-FA1 ( FANCA -/- ) vs CCH-SCC-FA1 ( FANCA Compl ) (F) and DU145 WT vs DU145_ FANCA KO (G) are illustrated.
    Figure Legend Snippet: (A) Western blot illustrating FANCA protein loss in FANCA-deficient cell lines. (B,C) Lack of FANCD2 monoubiquitination, a hallmark of FA pathway activation, in FANCA-deficient cells. (D,E) FANCA-deficient cells show increased vulnerability to MMC: drug response curves for CCH-SCC-FA1 ( FANCA -/- ) vs CCH-SCC-FA1 ( FANCA Compl ) (D) and DU145 WT vs DU145_ FANCA KO (E) are illustrated. (F,G) FANCA-deficient cells show increased vulnerability to cisplatin: drug response curves for CCH-SCC-FA1 ( FANCA -/- ) vs CCH-SCC-FA1 ( FANCA Compl ) (F) and DU145 WT vs DU145_ FANCA KO (G) are illustrated.

    Techniques Used: Western Blot, Activation Assay

    Cells were exposed to 1 µM MMC for 24 hours vs control conditions (DMSO) and imaged via confocal microscopy using Zeiss LSM 710 or Zeiss LSM 980 (63x). (A,C,E) Representative immunofluorescence images for CCH-SCC-FA1 ( FANCA Compl ) vs CCH-SCC-FA1 ( FANCA -/- ) (A), DU145 WT vs DU145_ FANCA KO (C), and RPE1 WT vs RPE1_ FANCA KD (E); scale represents 20 µm. (B, D, F) FANCD2 foci quantification for the same FANCA-deficient vs proficient cell lines. The number of foci per cell are represented, and statistical significance was calculated with the unpaired t-test.
    Figure Legend Snippet: Cells were exposed to 1 µM MMC for 24 hours vs control conditions (DMSO) and imaged via confocal microscopy using Zeiss LSM 710 or Zeiss LSM 980 (63x). (A,C,E) Representative immunofluorescence images for CCH-SCC-FA1 ( FANCA Compl ) vs CCH-SCC-FA1 ( FANCA -/- ) (A), DU145 WT vs DU145_ FANCA KO (C), and RPE1 WT vs RPE1_ FANCA KD (E); scale represents 20 µm. (B, D, F) FANCD2 foci quantification for the same FANCA-deficient vs proficient cell lines. The number of foci per cell are represented, and statistical significance was calculated with the unpaired t-test.

    Techniques Used: Control, Confocal Microscopy, Immunofluorescence



    Similar Products

    anti fancj  (Cell Signaling Technology Inc)
    94
    Cell Signaling Technology Inc anti fancj
    Anti Fancj, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti fancj/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    anti fancj - by Bioz Stars, 2026-04
    94/100 stars
    		  Buy from Supplier
    anti fancd2  (Cell Signaling Technology Inc)
    94
    Cell Signaling Technology Inc anti fancd2
    Anti Fancd2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti fancd2/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    anti fancd2 - by Bioz Stars, 2026-04
    94/100 stars
    		  Buy from Supplier
    rabbit anti fancd2 antibody  (Novus Biologicals)
    95
    Novus Biologicals rabbit anti fancd2 antibody
    (A) Western blot illustrating FANCA protein loss in FANCA-deficient cell lines. (B,C) Lack of <t>FANCD2</t> monoubiquitination, a hallmark of FA pathway activation, in FANCA-deficient cells. (D,E) FANCA-deficient cells show increased vulnerability to MMC: drug response curves for CCH-SCC-FA1 ( FANCA -/- ) vs CCH-SCC-FA1 ( FANCA Compl ) (D) and DU145 WT vs DU145_ FANCA KO (E) are illustrated. (F,G) FANCA-deficient cells show increased vulnerability to cisplatin: drug response curves for CCH-SCC-FA1 ( FANCA -/- ) vs CCH-SCC-FA1 ( FANCA Compl ) (F) and DU145 WT vs DU145_ FANCA KO (G) are illustrated.
    Rabbit Anti Fancd2 Antibody, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti fancd2 antibody/product/Novus Biologicals
    Average 95 stars, based on 1 article reviews
    rabbit anti fancd2 antibody - by Bioz Stars, 2026-04
    95/100 stars
    		  Buy from Supplier
    fancd2  (Cell Signaling Technology Inc)
    94
    Cell Signaling Technology Inc fancd2
    (A) Western blot illustrating FANCA protein loss in FANCA-deficient cell lines. (B,C) Lack of <t>FANCD2</t> monoubiquitination, a hallmark of FA pathway activation, in FANCA-deficient cells. (D,E) FANCA-deficient cells show increased vulnerability to MMC: drug response curves for CCH-SCC-FA1 ( FANCA -/- ) vs CCH-SCC-FA1 ( FANCA Compl ) (D) and DU145 WT vs DU145_ FANCA KO (E) are illustrated. (F,G) FANCA-deficient cells show increased vulnerability to cisplatin: drug response curves for CCH-SCC-FA1 ( FANCA -/- ) vs CCH-SCC-FA1 ( FANCA Compl ) (F) and DU145 WT vs DU145_ FANCA KO (G) are illustrated.
    Fancd2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fancd2/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    fancd2 - by Bioz Stars, 2026-04
    94/100 stars
    		  Buy from Supplier
    rabbit anti fancd2  (Novus Biologicals)
    95
    Novus Biologicals rabbit anti fancd2
    (A) Western blot illustrating FANCA protein loss in FANCA-deficient cell lines. (B,C) Lack of <t>FANCD2</t> monoubiquitination, a hallmark of FA pathway activation, in FANCA-deficient cells. (D,E) FANCA-deficient cells show increased vulnerability to MMC: drug response curves for CCH-SCC-FA1 ( FANCA -/- ) vs CCH-SCC-FA1 ( FANCA Compl ) (D) and DU145 WT vs DU145_ FANCA KO (E) are illustrated. (F,G) FANCA-deficient cells show increased vulnerability to cisplatin: drug response curves for CCH-SCC-FA1 ( FANCA -/- ) vs CCH-SCC-FA1 ( FANCA Compl ) (F) and DU145 WT vs DU145_ FANCA KO (G) are illustrated.
    Rabbit Anti Fancd2, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti fancd2/product/Novus Biologicals
    Average 95 stars, based on 1 article reviews
    rabbit anti fancd2 - by Bioz Stars, 2026-04
    95/100 stars
    		  Buy from Supplier
    rabbit anti fancd2 novus cat  (Novus Biologicals)
    95
    Novus Biologicals rabbit anti fancd2 novus cat
    (A) Western blot illustrating FANCA protein loss in FANCA-deficient cell lines. (B,C) Lack of <t>FANCD2</t> monoubiquitination, a hallmark of FA pathway activation, in FANCA-deficient cells. (D,E) FANCA-deficient cells show increased vulnerability to MMC: drug response curves for CCH-SCC-FA1 ( FANCA -/- ) vs CCH-SCC-FA1 ( FANCA Compl ) (D) and DU145 WT vs DU145_ FANCA KO (E) are illustrated. (F,G) FANCA-deficient cells show increased vulnerability to cisplatin: drug response curves for CCH-SCC-FA1 ( FANCA -/- ) vs CCH-SCC-FA1 ( FANCA Compl ) (F) and DU145 WT vs DU145_ FANCA KO (G) are illustrated.
    Rabbit Anti Fancd2 Novus Cat, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti fancd2 novus cat/product/Novus Biologicals
    Average 95 stars, based on 1 article reviews
    rabbit anti fancd2 novus cat - by Bioz Stars, 2026-04
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Western blot illustrating FANCA protein loss in FANCA-deficient cell lines. (B,C) Lack of FANCD2 monoubiquitination, a hallmark of FA pathway activation, in FANCA-deficient cells. (D,E) FANCA-deficient cells show increased vulnerability to MMC: drug response curves for CCH-SCC-FA1 ( FANCA -/- ) vs CCH-SCC-FA1 ( FANCA Compl ) (D) and DU145 WT vs DU145_ FANCA KO (E) are illustrated. (F,G) FANCA-deficient cells show increased vulnerability to cisplatin: drug response curves for CCH-SCC-FA1 ( FANCA -/- ) vs CCH-SCC-FA1 ( FANCA Compl ) (F) and DU145 WT vs DU145_ FANCA KO (G) are illustrated.

    Journal: bioRxiv

    Article Title: Aurora kinase A is a synthetic lethal target in FANCA-deficient cancers

    doi: 10.64898/2026.02.04.703705

    Figure Lengend Snippet: (A) Western blot illustrating FANCA protein loss in FANCA-deficient cell lines. (B,C) Lack of FANCD2 monoubiquitination, a hallmark of FA pathway activation, in FANCA-deficient cells. (D,E) FANCA-deficient cells show increased vulnerability to MMC: drug response curves for CCH-SCC-FA1 ( FANCA -/- ) vs CCH-SCC-FA1 ( FANCA Compl ) (D) and DU145 WT vs DU145_ FANCA KO (E) are illustrated. (F,G) FANCA-deficient cells show increased vulnerability to cisplatin: drug response curves for CCH-SCC-FA1 ( FANCA -/- ) vs CCH-SCC-FA1 ( FANCA Compl ) (F) and DU145 WT vs DU145_ FANCA KO (G) are illustrated.

    Article Snippet: Cells were then incubated with the primary antibody for 1 hour at RT, rabbit anti-FANCD2 antibody (Novus Biologicals, NB100-182, 1:500 in SB) or mouse anti-FANCD2 antibody (Novus Biologicals, NB100-316, 1:500 in SB).

    Techniques: Western Blot, Activation Assay

    Cells were exposed to 1 µM MMC for 24 hours vs control conditions (DMSO) and imaged via confocal microscopy using Zeiss LSM 710 or Zeiss LSM 980 (63x). (A,C,E) Representative immunofluorescence images for CCH-SCC-FA1 ( FANCA Compl ) vs CCH-SCC-FA1 ( FANCA -/- ) (A), DU145 WT vs DU145_ FANCA KO (C), and RPE1 WT vs RPE1_ FANCA KD (E); scale represents 20 µm. (B, D, F) FANCD2 foci quantification for the same FANCA-deficient vs proficient cell lines. The number of foci per cell are represented, and statistical significance was calculated with the unpaired t-test.

    Journal: bioRxiv

    Article Title: Aurora kinase A is a synthetic lethal target in FANCA-deficient cancers

    doi: 10.64898/2026.02.04.703705

    Figure Lengend Snippet: Cells were exposed to 1 µM MMC for 24 hours vs control conditions (DMSO) and imaged via confocal microscopy using Zeiss LSM 710 or Zeiss LSM 980 (63x). (A,C,E) Representative immunofluorescence images for CCH-SCC-FA1 ( FANCA Compl ) vs CCH-SCC-FA1 ( FANCA -/- ) (A), DU145 WT vs DU145_ FANCA KO (C), and RPE1 WT vs RPE1_ FANCA KD (E); scale represents 20 µm. (B, D, F) FANCD2 foci quantification for the same FANCA-deficient vs proficient cell lines. The number of foci per cell are represented, and statistical significance was calculated with the unpaired t-test.

    Article Snippet: Cells were then incubated with the primary antibody for 1 hour at RT, rabbit anti-FANCD2 antibody (Novus Biologicals, NB100-182, 1:500 in SB) or mouse anti-FANCD2 antibody (Novus Biologicals, NB100-316, 1:500 in SB).

    Techniques: Control, Confocal Microscopy, Immunofluorescence